Sort
82,697 grants matching “vaccine development”
Development of botulinum neurotoxin immunotherapy
$865,401University Of California San Francisco · U01 · FY2003 · AI
" Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons.â
$865,387Gaurav Das Gaiha · Massachusetts General Hospital · R01 · FY2025 · AI
Non-Human Primate Core
$865,364Mario Roederer · National Institute Of Allergy And Infectious Diseases · ZIC · FY2011 · AI
Project 1: CRISPR screens to discover regulators of CD8 and CD4 cell fates and function
$865,355Arlene H Sharpe · Harvard Medical School · U19 · FY2021 · AI
Immune Dysfunction in HIV+ Opioid Users
$865,279Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2024 · DA
Multivalent DNA vaccine-mediated protection against Tuberculosis
$865,253David B. Weiner · Wistar Institute · R01 · FY2022 · AI
Recombinant life attenuated vaccine against Argentine hemorrhagic fever
$865,253Slobodan Paessler · University Of Texas Med Br Galveston · R01 · FY2012 · AI
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens
$865,153Beatrice H Hahn · University Of Pennsylvania · R37 · FY2025 · AI
Human pluripotent stem cells
$865,069Pamela Robey · National Institute Of Neurological Disorders And Stroke · ZIC · FY2021 · NS
Characterizing pediatric genomes through an optimized sequencing approach
$865,000Shawn E Levy · Hudson-Alpha Institute For Biotechnology · U24 · FY2018 · HD
Neutralizing Botulinum Neurotoxin with Human Antibodies
$864,970Sri International · U01 · FY2005 · AI
Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza
$864,948Gregory Davenport · Tff Pharmaceuticals, Inc. · R44 · FY2023 · AI
Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria
$864,868Peter Rice · Univ Of Massachusetts Med Sch Worcester · N01 · FY2021 · AI
Development of vaccination strategies to elicit broadly protective immunity against influenza
$864,833Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2019 · AI
Nikkomycin Z treatment of primary pneumonia due to Coccidioides
$864,797David Larwood · Valley Fever Solutions, Inc. · U01 · FY2015 · AI
A Novel Th17-inducing Mucosal Vaccine for Tuberculosis
$864,661Shabaana A. Khader · Washington University · R01 · FY2022 · AI
First-in-human study of a potent anti-HBsAg neutralizing antibody
$864,658Marina Caskey · Rockefeller University · U01 · FY2023 · AI
Integrated Multi-omics of Melioidosis
$864,642Timothy Eoin West · University Of Washington · R01 · FY2020 · AI
Computational Models of Infectious Disease Threats
$864,530Donald S. Burke · University Of Pittsburgh At Pittsburgh · U01 · FY2006 · GM
Preclinical Development of a Novel and Powerful Immunotherapeutic
$864,478Susan Dana Jones · Immurx Llc · R44 · FY2013 · AI
Project 1 - Profectus Biosciences, Inc.
$864,462John H Eldridge · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2021 · AI
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
$864,458Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2017 · AI
JAK-STAT Control of Zika Virus-Induced Fetal Injury
$864,353Kristina M Adams Waldorf · University Of Washington · R01 · FY2021 · AI
Influenza Viral Genomics and Evolution
$864,315Jeffery Taubenberger · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Development of Novel Immunogens for Vaccines to HIV-1
$864,291Robert Gerald Whalen · Maxygen, Inc. · P01 · FY2007 · AI